Endovascular Treatment of Unruptured Paraclinoid Aneurysms: Single-Center Experience with 400 Cases and Literature Review

K. Shimizu; H. Imamura; Y. Mineharu; H. Adachi; C. Sakai; N. Sakai

doi:10.3174/ajnr.A4577

Abstract

BACKGROUND AND PURPOSE: Paraclinoid aneurysms have been increasingly treated endovascularly. The natural history of these aneurysms has gradually been elucidated. The purpose of this study was to assess the safety and efficacy of endovascular treatment for these aneurysms.

MATERIALS AND METHODS: We performed a retrospective review of 377 patients with 400 paraclinoid aneurysms treated between January 2006 and December 2012. Their clinical records, endovascular reports, and radiologic and clinical outcomes were analyzed. Because aneurysms ≥7 mm are at higher risk of rupture, we classified aneurysms as small (<7 mm) or large (≥7 mm).

RESULTS: Overall, 115 of the 400 aneurysms (28.8%) were large (≥7 mm). Thromboembolic complications were found significantly more often with large aneurysms than with small ones (7.4% vs 1.0%, P = .001). Hemorrhagic complications were found only with small aneurysms (0.7%). The 6-month morbidity rates were similar for small (1.0%) and large (0.8%) aneurysms. Immediate angiographic outcomes were similar (P = .37), whereas recurrences and retreatment occurred more frequently with large aneurysms (P = .001 and P = .007, respectively). Multivariate analysis showed that aneurysm size was the only independent predictor for recurrence (P = .005). Most recurrences (81%) were detected by scheduled angiography at 6 months.

CONCLUSIONS: Aneurysm size influenced the type of complication (thromboembolic or hemorrhagic) and the recurrence rate. Given the approximately 1% annual rupture rate for aneurysms ≥7 mm, analysis of our data supports the rationale of using prophylactic endovascular treatment for unruptured paraclinoid aneurysms ≥7 mm.

ABBREVIATION:

UCAS: Unruptured Cerebral Aneurysm Study

Paraclinoid aneurysms are located in the clinoid and ophthalmic segments of the ICA.¹ Because of the anatomic structures adjacent to the segments of the ICA (eg, anterior clinoid process, cavernous sinus, optic apparatus), microsurgical treatment of a paraclinoid aneurysm can be challenging.² With the development of novel devices and the need for less-invasive treatment, an increasing number of paraclinoid aneurysms have been treated by endovascular treatment. The natural history of unruptured intracranial aneurysms has been reported as represented by the International Study of Unruptured Intracranial Aneurysms and the Unruptured Cerebral Aneurysm Study (UCAS) by Japanese investigators.^{3⇓⇓⇓⇓–8} According to these studies, the size and location of the aneurysms were regarded as leading predictors of rupture. The UCAS Japan investigators reported that the annual rupture rate of paraclinoid aneurysms was 1% overall when they were 7–24 mm in largest dimension.⁷ Therefore, aneurysms ≥7 mm would be good candidates for prophylactic endovascular treatment. There have been no studies reported, however, that analyzed the complication and recurrence rates relative to the annual rupture rate.^{9⇓⇓⇓⇓⇓–15}

The purpose of the present study was to assess the safety and efficacy of endovascular treatment for paraclinoid aneurysms in a cohort of 400 cases. The advantage of this study was that we could estimate the clinical outcome of endovascular treatment for these aneurysms in comparison with the natural history of an aneurysm of the same size in the same ethnic population by using the UCAS Japan data.

Materials and Methods

Study Population

Between January 2006 and December 2012, a total of 889 endovascular coil embolizations were conducted for unruptured intracranial aneurysms at Kobe City Medical Center General Hospital. Among these procedures, 415 were applied to 403 paraclinoid aneurysms in 380 patients. Surgical clipping was chosen for only 6 paraclinoid aneurysms during this period. Three aneurysms in 3 patients were excluded because they were treated by parent artery occlusion. Thus, a total of 400 paraclinoid aneurysms in 377 patients were included in the study.

Paraclinoid aneurysms at our institution are categorized as anterior wall, ventral paraclinoid, true ophthalmic, or carotid cave aneurysms according to the al-Rodhan et al¹⁶ classification modified by Iihara et al.¹⁷ Aneurysm size was categorized as small (<7 mm) or large (≥7 mm). We retrospectively reviewed the medical records and radiologic data for these patients. Informed consent for the treatment was obtained from all the patients, and our institutional review board approved the protocol.

The patient characteristics used in this analysis included age, sex, medical history (hypertension, diabetes mellitus, dyslipidemia, polycystic kidney, number of aneurysms, smoking habit, family history of SAH), and neurologic symptoms. Radiologic characteristics included dome and neck size, dome:neck ratio, and location of aneurysms.

Endovascular Procedures

Procedures were performed with the patient under local anesthesia. All the patients were pretreated with daily doses of 100 mg of aspirin and 75 mg of clopidogrel for >5 days in preparation for a stent-assisted technique. After femoral puncture, a bolus of 4000–5000 U of heparin was administered intravenously, followed by intermittent intravenous infusion of 1000–2000 U of heparin to maintain the activated clotting time at 2 times the patient's baseline throughout the procedure. After the procedure, the patients were administered continuous intravenous argatroban 60 mg/day for 48 hours. Patients who underwent a stent-assisted procedure continued treatment with the dual antiplatelet therapy described above for 6 months, followed by 100 mg of aspirin or 75 mg of clopidogrel per day indefinitely. Otherwise, patients were treated with 100 mg of aspirin or 75 mg of clopidogrel per day for 6 months, followed by no antiplatelet therapy.

The decision about whether a stent-assisted technique should be used was based on the risk of coil protrusion into the parent artery. We started measuring aspirin-reaction units and P2Y12 reaction units in 2010 and used these values for the decision-making process in 2013. Therefore, the antiplatelet function test was not taken into account for the selection of antiplatelet drugs during the study period.

Angiographic Outcomes and Follow-Up

Angiographic outcomes were divided into 3 categories: complete occlusion, neck remnant, body filling.¹⁸ Immediate angiographic outcomes were assessed by using DSA on the date of treatment. Follow-up angiographic outcomes were assessed by DSA and/or MRA. Recurrence was defined as any decrease in the occluded area demonstrated by DSA or MRA. Recurrences were subdivided into those that required intervention and those that were treated conservatively. For each aneurysm, angiographic follow-up by DSA was scheduled for 6 months after treatment. Radiographic follow-up by MRA was performed at various intervals. When recanalization was suspected, DSA was performed to identify indications for additional treatment.

Complications related to the procedures were recorded based on symptoms and radiologic examination. Ischemic and hemorrhagic complications were diagnosed by using CT and MRI. When patients displayed neurologic symptoms, including headache, radiologic examinations were conducted just after treatment. Otherwise, those examinations were routinely conducted on the day after treatment. Other complications, such as visual impairment and oculomotor nerve palsy, were considered to be procedure-related based on the time of onset and radiographic analysis. Good clinical outcome was defined as an mRS of 0–2 at 6 months. Complications that left a neurologic deficit at 6 months were described as permanent morbidity.

In this study, aneurysm size was classified as small (<7 mm) or large (≥7 mm). We compared the results according to the aspects of the aneurysm location, therapeutic strategy (adjunctive technique), angiographic outcome, recurrence rate, frequency of complications, and subsequent clinical outcomes.

Statistical Analysis

The χ² test, Fisher exact test, and Student t test were used as appropriate. Factors found to be predictive for recurrence in the univariate analysis (P < .15) were entered into a multivariate logistic regression analysis. A value of P < .05 was considered to indicate statistical significance. All statistical analyses were performed with JMP software, version 10.0 (SAS Institute, Cary, North Carolina).

Results

Demographics

A total of 400 unruptured paraclinoid aneurysms in 377 patients were treated endovascularly. Characteristics of the patients and aneurysms are summarized in Table 1. Two hundred eighty-five aneurysms (71.3%) were small, and 350 (87.5%) occurred in female patients. The mean age of the patients was 56.2 ± 11.2 years (range, 27–80 years), and 23 patients (6.1%) were ≥70 years. The numbers of patients who had a medical history of hypertension, diabetes mellitus, dyslipidemia, or polycystic kidney disease were 151 (40.1%), 19 (5.0%), 83 (22.0%), and 0, respectively. Seventy-eight patients (20.7%) were former or current smokers, 45 (11.9%) had a family history of SAH, and 86 (22.6%) had multiple aneurysms. Three hundred eighty-three aneurysms (95.8%) were asymptomatic. Variables that were seen significantly more often or were more frequently observed in patients with large aneurysms included older age (P = .003), former or current smoking habit (P = .042), and symptoms caused by the aneurysm (P = .002).

View this table:

Table 1:

Characteristics of patients and aneurysms^{^a}

Radiologic characteristics of the aneurysms are summarized in Table 2. The mean dome:neck ratio was significantly lower with small aneurysms (1.6 ± 0.4) than with large aneurysms (2.2 ± 0.7) (P < .001). The location of aneurysms was also significantly different between the groups (P = .003). The most prevalent location for small aneurysms was the carotid cave (42.8%), whereas that for large aneurysms was the anterior wall (33.0%).

View this table:

Table 2:

Radiologic characteristics of aneurysms

Treatment Specifics

Treatment strategies are summarized in Table 3. All aneurysms were treated by endovascular coil embolization. A stent-assisted technique was more frequently used for large aneurysms (43.5%) than for small aneurysms (17.2%) (P < .001). The procedures failed for 3 small aneurysms (1.1%) and 1 large aneurysm (0.87%). Among these 4 failures, 2 small aneurysms were re-treated on another day by using different strategies. In the other 2 cases, the patients refused retreatment.

View this table:

Table 3:

Treatment strategies and results

Angiographic Outcomes

Details about the angiographic outcomes are shown in Table 3. Follow-up angiography (DSA or MRA) at 6 months was available for 386 aneurysms (96.5%). Among them, 273 (68.3%) were examined by DSA. MRA at 2 years (18 ± 6 months) was available for 291 aneurysms (72.8%). A total of 37 aneurysms (9.6%) recurred during the follow-up period, with 81% of them (30/37) detected by a scheduled angiography at 6 months.

Among the small aneurysms, immediate complete occlusion was achieved for 29 (10.2%), a neck remnant for 80 (28.1%), and body filling for 176 (61.8%). Radiologic follow-up was available for 96.5% (275/285), with a mean interval of 30 ± 19 months (range, 6–96 months). During the follow-up period, the complete occlusion rate increased to 72.4%. Eighteen aneurysms (6.5%) recurred, and retreatment was needed for 3 of them (1.1%).

For the large aneurysms, immediate complete occlusion was achieved in 9 (7.8%), a neck remnant in 40 (34.8%), and body filling in 66 (57.4%). Radiologic follow-up was available for 96.5% (111/115), with a mean interval of 36 ± 21 months (range, 6–83 months). During the follow-up period, complete occlusion was achieved in 55.0%. There were 19 recurrences (17.1%), and 7 (6.3%) underwent retreatment. The distributions of the immediate angiographic outcomes were almost the same in the small and large aneurysm groups (P = .37). During the follow-up period, however, the rate of body filling was significantly higher for large aneurysms than for small aneurysms (P < .001). As a result, the numbers of recurrences and retreatments were significantly higher for large aneurysms (P = .001 and P = .007, respectively).

The following factors were evaluated as predictors of recurrence: age, sex, location of the aneurysm, side, large (≥7 mm), wide neck (≥4 mm or aspect [dome:neck] ratio of ≤2), medical history (hypertension, diabetes mellitus, smoking habit), body filling at initial treatment, use of stent-assisted technique, ischemic complication (Table 4). The univariate analysis indicated that only the large size of an aneurysm was a significant predictor of recurrence (P = .001). In the multivariate analysis, large size was also a significant (P = .005) predictor after correction by side and ischemic complication (P = .101 and 0.097 in the univariate analysis, respectively). To show the trend for what we assessed to be major recanalization, the predictors of retreatment were also subjected to univariate analysis (Table 5). Among the factors listed above, large size (P = .008) and former or current smoking habit (P = .031) were associated with retreatment.

View this table:

Table 4:

Predictors of recurrence^{^a}

View this table:

Table 5:

Predictors of the need for retreatment^{^a}

Procedure-Related Complications

There were 16 procedural complications (3.9%) (Table 6). Thromboembolic complications were most frequent, which occurred in 12 patients (2.9%). Among them, permanent morbidity was observed in 3 patients (0.7%). Permanent morbidity included in-stent thrombosis that resulted in ICA occlusion in 1 patient and visual impairment due to an embolism in the ophthalmic artery in 2 patients. In the other 9 patients (2.2%), the symptoms were mild and resolved spontaneously within a few days. Thromboembolic complications were found significantly more often in patients with large aneurysms (9/122) than in those with small ones (3/290) (P = .001).

View this table:

Table 6:

Complications

Hemorrhagic complications (intraprocedural aneurysm rupture) occurred in 2 patients (0.5%), both with small aneurysms. One of them (0.2%) resulted in permanent morbidity. Other complications were observed in 2 patients (0.5%). Visual disturbance and oculomotor nerve palsy due to compression by coil mass occurred in 1 patient each (0.2%). Neither resulted in permanent morbidity. Complications associated with the coil mass were seen only in large aneurysms. Overall, permanent morbidity rates were 1.0% for small aneurysms and 0.8% for large ones (P = 1.0).

Long-Term Clinical Outcome

In the small-aneurysm group, among 273 patients with 285 aneurysms, clinical follow-up was available for 268 patients. The mean clinical follow-up duration was 32 ± 19 months (range, 6–97 months). Poor clinical outcomes were observed in 2 patients (0.7%), both of which were procedure-related (mRS = 3 in both cases).

Among 113 patients with 115 large aneurysms, clinical follow-up was available for 112 patients. The mean clinical follow-up duration was 39 ± 21 months (range, 6–88 months). Poor clinical outcomes were observed in 3 patients (2.7%). All were unrelated to the procedure and included cerebral infarction (mRS = 4), cerebral hemorrhage (mRS = 4), and pontine hemorrhage (mRS = 6). One patient with a large aneurysm (9.0 mm) had aneurysmal rupture owing to recanalization 2 months after treatment, but the patient had a good clinical outcome after additional endovascular treatment (mRS = 0).

Discussion

Unruptured intracranial aneurysms are common and occurred in approximately 1%–2% of the population, as reviewed by Vlak et al.¹⁹ Because most unruptured intracranial aneurysms are asymptomatic and are found incidentally, treatment should be considered after balancing the natural history of the aneurysm with the risk posed by the treatment. Prospective data for the natural history of unruptured intracranial aneurysms by the International Study of Unruptured Intracranial Aneurysms and UCAS Japan investigators showed that the annual rupture rate increased for aneurysms that were ≥7 mm. The presence of a daughter sac and a history of SAH increased the rupture rate.^5,7 In the Japanese cohort, the annual rupture rates for paraclinoid aneurysms were approximately 0.1%, 1%, and 10% when they were <7 mm, 7–24 mm, and >25 mm, respectively, in size.⁷ Analysis of our data showed that the 6-month morbidity and mortality rates for aneurysms ≥7 mm were acceptably low (0.8% and 0%, respectively). The retreatment rate with a mean follow-up interval of 39 months was also acceptable (6.3%). Prophylactic treatment of these unruptured aneurysms could be rationalized. The indications for endovascular treatment of small paraclinoid aneurysms, however, should be carefully assessed on an individual basis after considering the patient and aneurysmal factors, such as medical comorbidities, patient age, a history of SAH, the presence of a daughter sac, aneurysmal size, and aneurysmal enlargement. Treatment may be considered when patients are predicted to be at relatively high risk of rupture because the 6-month morbidity and retreatment rates for small aneurysms are low (1.0% and 1.1%, respectively).

Unruptured paraclinoid aneurysms have been increasingly treated endovascularly for anatomic reasons.^{9⇓⇓⇓⇓⇓–15,20} Colli et al² reviewed microsurgical outcomes of paraclinoid aneurysms, which showed that total complication rates were 21.3%–41.7%. The complications included intraoperative aneurysm rupture in 0.8%–14.3%, occlusion of the ICA in 1.2%–13.6%, and visual impairment in 1.8%–33.3%.² Mortality rates associated with microsurgical treatment in unruptured cases were 0%–10.0%.² Total neurologic complications associated with endovascular coil embolization of unruptured paraclinoid aneurysms reported after 2010, including this study, were 1.4%–6.7% and mortality was 0%,^{10⇓–12,14,15,21} which demonstrated that endovascular treatment was more appropriate for prophylactic treatment of these aneurysms. Paraclinoid aneurysms are increasingly being treated with flow-diversion stents, which may further reduce the procedural risks associated with endovascular treatment.^{22⇓⇓–25}

Angiographic and clinical outcomes from previous studies are summarized in Table 7. The immediate complete occlusion rate in our series was low (9.5%) compared with those in earlier studies (28.2%–86.6%).^{9⇓⇓⇓⇓⇓–15,21} The complete occlusion rate in the late stage, however, reached approximately 70%, which was similar to those reported in previous studies (54.0%–87.8%).^{9⇓⇓⇓⇓⇓–15,21} The results indicated that aggressive coil packing was not essential for good angiographic outcomes during the late stage because of the possibility of subsequent thrombus formation around the coil mass.

View this table:

Table 7:

Angiographic and clinical outcomes in recent series

The recurrence rate in this region differed among studies, which ranged from 5.0% to 23.1%.^{9⇓⇓⇓⇓⇓–15,21} D'Urso et al¹⁵ reported that stent-assisted coil embolization was associated with a lower recurrence rate than that seen with a simple technique (6% vs 19%, P = .171). Their results were replicated by Yadla et al²¹ (9.4% vs 24.6%, P = .03). In our series, however, stent use did not affect the recurrence rate (8.3% vs 10.0%, P = .63). This could be due to different indications for using the stent-assisted technique among studies. The proportion of stent-assisted embolization was higher in our series, which indicated that the total recurrence rate could be reduced if the stent-assisted technique were properly applied for likely-to-recur aneurysms in this region.

We showed that the mean interval from the initial treatment to recurrence was 7.8 ± 5.0 months, and recurrence was rarely detected after the first posttreatment year (Figure). Consistent with our results, Wang et al¹⁰ reported that recurrence was detected in 12.5% of cases at a mean interval of 9.89 ± 5.21 months. Although Yadla et al²¹ showed that recurrence was detected in 17.8% of cases, at a mean interval of 28.3 months, the difference might be caused by the scheduled timing of follow-up angiography. Follow-up angiography at 6–12 months would be reasonable for detecting late recanalization. Aneurysm rupture after recanalization has been rare, with only 3 cases reported to date, including 1 case in this study (Table 7). Still, it is of note that the rupture occurred as early as 2 months after coil embolization in these cases. Thus, additional follow-up MRA at 1 month may be needed to detect acute recanalization that could cause aneurysmal rupture.

Figure.

Recurrence rates after the initial treatment according to the size of the aneurysms. Most recurrences were detected within 1 year after treatment.

Previous studies showed that the size of the aneurysms was associated with the recurrence rate,^10,12,15 and analysis of our data indicated that aneurysms of ≥7 mm were at a higher risk of recurrence. Previous reports, however, did not analyze the relationship between aneurysm size and the type of complications. Analysis of our data indicated that large aneurysms were likely to be associated with ischemic complications and that small aneurysms were associated with hemorrhagic complications. This finding was consistent with previously published data by Shigematsu et al.²⁶

There were several limitations to our study. First, the study was designed as a retrospective review based on a single-center experience. Therefore, it might not be suitable to compare the data with those of a prospective cohort study (UCAS Japan). However, because of the relatively high risk of rupture for large aneurysms in this region, it is not reasonable to conduct a prospective controlled trial. Cost-effective analysis may provide further support for the rationale of prophylactic treatment for unruptured aneurysms.

Second, indications for endovascular treatment of small aneurysms were addressed in an individualized fashion according to the patient age, history of SAH, family history of SAH, size, shape (ie, the presence of a daughter sac) and multiplicity of the aneurysm, aneurysmal enlargement, patient anxiety and mental status, and comorbidities (eg, hypertension). Many of these parameters can be associated with an increased risk of rupture for small aneurysms.²⁷ However, such parameters were not precisely provided, and we could not determine whether the decision-making process was consistent. Indications might have been altered after publication of data from large cohorts, such as in the Small Unruptured Intracranial Aneurysm Verification Study or UCAS Japan.^7,27 This was also a limitation that stems from the retrospective nature of our study.

Third, platelet function testing was not performed in this study population, though there is evidence that the hyporesponse to clopidogrel is associated with increased risk of thromboembolic complications.^{28⇓⇓–31} Selection of the antiplatelet drugs might have influenced the increased incidence of thromboembolic events in large aneurysms that were treated by using the stent-assisted technique.

Conclusions

Endovascular treatment of unruptured paraclinoid aneurysms ≥7 mm can be achieved with high technical success, low complication rates, and excellent long-term outcomes. Treatment of unruptured paraclinoid aneurysms <7 mm may be considered in patients, based on an individualized assessment of risk factors, including medical comorbidities, patient age, ethnicities, aneurysm characteristics, and history of SAH.

Footnotes

Disclosures: Nobuyuki Sakai—UNRELATED: Grants/Grants Pending: Terumo (modest)*; Payment for Lectures (including service on speakers bureaus): Codman, Covidien, Stryker, Terumo, Comments: Modest. *Money paid to the institution.

Indicates open access to non-subscribers at www.ajnr.org

REFERENCES

1.↵
2. Kim JM,
3. Romano A,
4. Sanan A, et al
. Microsurgical anatomic features and nomenclature of the paraclinoid region. Neurosurgery 2000;46:670–80; discussion 680–82 pmid:10719864
CrossRef PubMed
2.↵
2. Colli BO,
3. Carlotti CG,
4. Assirati JA, et al
. Results of microsurgical treatment of paraclinoid carotid aneurysms. Neurosurg Rev 2013;361:99–114; discussion 114–15 doi:10.1007/s10143-012-0415-0 pmid:22898891
CrossRef PubMed
3.↵
2. Lee EJ,
3. Lee HJ,
4. Hyun MK, et al
. Rupture rate for patients with untreated unruptured intracranial aneurysms in South Korea during 2006–2009. J Neurosurg 2012;117:53–59 doi:10.3171/2012.3.JNS111221 pmid:22519434
CrossRef PubMed
4.↵
2. Juvela S,
3. Porras M,
4. Poussa K
. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. J Neurosurg 2000;93:379–87 pmid:10969934
CrossRef PubMed
5.↵
Unruptured intracranial aneurysms–risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Engl J Med 1998:339:1725–33 doi:10.1056/NEJM199812103392401 pmid:9867550
CrossRef PubMed
6.↵
2. Juvela S,
3. Poussa K,
4. Lehto H, et al
. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. Stroke 2013;44:2414–21 doi:10.1161/STROKEAHA.113.001838 pmid:23868274
Abstract/FREE Full Text
7.↵
2. Morita A,
3. Kirino T, et al
UCAS Japan Investigators, Morita A, Kirino T, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012;366:2474–82 doi:10.1056/NEJMoa1113260 pmid:22738097
CrossRef PubMed
8.↵
2. Wiebers DO,
3. Whisnant JP,
4. Huston J, et al
. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003:362:103–10 doi:10.1016/S0140-6736(03)13860-3 pmid:12867109
CrossRef PubMed
9.↵
2. Thornton J,
3. Aletich VA,
4. Debrun GM, et al
. Endovascular treatment of paraclinoid aneurysms. Surg Neurol 2000;54:288–99 doi:10.1016/S0090-3019(00)00313-X pmid:11136984
CrossRef PubMed
10.↵
2. Wang Y,
3. Li Y,
4. Jiang C, et al
. Endovascular treatment of paraclinoid aneurysms: 142 aneurysms in one centre. J Neurointerv Surg 2013;5:552–56 doi:10.1136/neurintsurg-2012-010494 pmid:23087381
Abstract/FREE Full Text
11.↵
2. Sun Y,
3. Li Y,
4. Li A
. Endovascular treatment of paraclinoid aneurysms. Interv Neuroradiol 2011;17:425–30 pmid:22192545
Abstract/FREE Full Text
12.↵
2. Sorimachi T,
3. Ito Y,
4. Morita K, et al
. Long-term follow-up of intra-aneurysmal coil embolization for unruptured paraclinoid aneurysms. Neurol Res 2012;34:864–70 doi:10.1179/1743132812Y.0000000084 pmid:22889587
CrossRef PubMed
13.↵
2. Park HK,
3. Horowitz M,
4. Jungreis C, et al
. Endovascular treatment of paraclinoid aneurysms: experience with 73 patients. Neurosurgery 2003;53:14–23; discussion 24 doi:10.1227/01.NEU.0000068789.08955.1C pmid:12823869
CrossRef PubMed
14.↵
2. Kwon BJ,
3. Im S-H,
4. Park JC, et al
. Shaping and navigating methods of microcatheters for endovascular treatment of paraclinoid aneurysms. Neurosurgery 2010;67:34–40 doi:10.1227/01.NEU.0000370891.67129.2F pmid:20559090
CrossRef PubMed
15.↵
2. D'Urso PI,
3. Karadeli HH,
4. Kallmes DF, et al
. Coiling for paraclinoid aneurysms: time to make way for flow diverters? AJNR Am J Neuroradiol 2012;33:1470–74 doi:10.3174/ajnr.A3009 pmid:22403773
Abstract/FREE Full Text
16.↵
2. al-Rodhan NR,
3. Piepgras DG,
4. Sundt TM
. Transitional cavernous aneurysms of the internal carotid artery. Neurosurgery 1993;33:993–96; discussion 997–98 doi:10.1227/00006123-199312000-00006 pmid:8134013
CrossRef PubMed
17.↵
2. Iihara K,
3. Murao K,
4. Sakai N, et al
. Unruptured paraclinoid aneurysms: a management strategy. J Neurosurg 2003;99:241–47 doi:10.3171/jns.2003.99.2.0241 pmid:12924695
CrossRef PubMed
18.↵
2. Ng P,
3. Khangure MS,
4. Phatouros CC, et al
. Endovascular treatment of intracranial aneurysms with Guglielmi detachable coils: analysis of midterm angiographic and clinical outcomes. Stroke 2002;33:210–17 doi:10.1161/hs0102.100486 pmid:11779912
Abstract/FREE Full Text
19.↵
2. Vlak MH,
3. Algra A,
4. Brandenburg R, et al
. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 2011;10:626–36 doi:10.1016/S1474-4422(11)70109-0 pmid:21641282
CrossRef PubMed
20.↵
2. Ferrell AS,
3. Lessne ML,
4. Alexander MJ, et al
. Visual complications after stent-assisted endovascular embolization of paraophthalmic and suprasellar variant superior hypophyseal aneurysms: the Duke Cerebrovascular Center experience in 57 patients. World Neurosurg 2012:78:289–94 doi:10.1016/j.wneu.2011.12.003 pmid:22381310
CrossRef PubMed
21.↵
2. Yadla S,
3. Campbell PG,
4. Grobelny B, et al
. Open and endovascular treatment of unruptured carotid-ophthalmic aneurysms: clinical and radiographic outcomes. Neurosurgery 2011;68:1434–43; discussion 1443 doi:10.1227/NEU.0b013e31820b4f85 pmid:21273934
CrossRef PubMed
22.↵
2. Fang S,
3. Lanzino G
. Paraclinoid aneurysms: is there a new endovascular standard? Neurol Res 2014;36:314–22 doi:10.1179/1743132814Y.0000000326 pmid:24617932
CrossRef PubMed
23.↵
2. Kim LJ,
3. Tariq F,
4. Levitt M, et al
. Multimodality treatment of complex unruptured cavernous and paraclinoid aneurysms. Neurosurgery 2014;74:51–61; discussion 61; quiz 61 doi:10.1227/NEU.0000000000000192 pmid:24089048
CrossRef PubMed
24.↵
2. Lanzino G,
3. Crobeddu E,
4. Cloft HJ, et al
. Efficacy and safety of flow diversion for paraclinoid aneurysms: a matched-pair analysis compared with standard endovascular approaches. AJNR Am J Neuroradiol 2012;33:2158–61 doi:10.3174/ajnr.A3207 pmid:22790243
Abstract/FREE Full Text
25.↵
2. Loumiotis I,
3. D'Urso PI,
4. Tawk R, et al
. Endovascular treatment of ruptured paraclinoid aneurysms: results, complications, and follow-up. AJNR Am J Neuroradiol 2012;33:632–37 doi:10.3174/ajnr.A2825 pmid:22173755
Abstract/FREE Full Text
26.↵
2. Shigematsu T,
3. Fujinaka T,
4. Yoshimine T, et al
. Endovascular therapy for asymptomatic unruptured intracranial aneurysms: JR-NET and JR-NET2 findings. Stroke 2013;44:2735–42 doi:10.1161/STROKEAHA.111.000609 pmid:23899916
Abstract/FREE Full Text
27.↵
2. Sonobe M,
3. Yamazaki T,
4. Yonekura M, et al
. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke 2010;41:1969–77 doi:10.1161/STROKEAHA.110.585059 pmid:20671254
Abstract/FREE Full Text
28.↵
2. Delgado Almandoz JE,
3. Crandall BM,
4. Scholz JM, et al
. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline embolization device. J Neurointerv Surg 2013;5(suppl 3):iii3–10 doi:10.1136/neurintsurg-2012-010582 pmid:23314576
Abstract/FREE Full Text
29.↵
2. Delgado Almandoz JE,
3. Kadkhodayan Y,
4. Crandall BM, et al
. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. J Neurointerv Surg 2014;6:767–73 doi:10.1136/neurintsurg-2013-010976 pmid:24353331
Abstract/FREE Full Text
30.↵
2. Lee DH,
3. Kim HS,
4. Kim SM, et al
. Change of platelet reactivity to antiplatelet therapy after stenting procedure for cerebral artery stenosis: VerifyNow antiplatelet assay before and after stenting. Neurointervention 2012;7:23–6 doi:10.5469/neuroint.2012.7.1.23 pmid:22454781
CrossRef PubMed
31.↵
2. Kang H-S,
3. Kwon BJ,
4. Kim JE, et al
. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206–10 doi:10.3174/ajnr.A2051 pmid:20223886
Abstract/FREE Full Text

Received June 4, 2015.
Accepted after revision August 21, 2015.

View Abstract

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

INTERVENTIONAL

Show more INTERVENTIONAL

ADULT BRAIN

Show more ADULT BRAIN

[1] 1.↵

Kim JM,
Romano A,
Sanan A, et al
. Microsurgical anatomic features and nomenclature of the paraclinoid region. Neurosurgery 2000;46:670–80; discussion 680–82 pmid:10719864
CrossRef PubMed

[3] Kim JM,

[4] Romano A,

[5] Sanan A, et al

[6] 2.↵

Colli BO,
Carlotti CG,
Assirati JA, et al
. Results of microsurgical treatment of paraclinoid carotid aneurysms. Neurosurg Rev 2013;361:99–114; discussion 114–15 doi:10.1007/s10143-012-0415-0 pmid:22898891
CrossRef PubMed

[8] Colli BO,

[9] Carlotti CG,

[10] Assirati JA, et al

[11] 3.↵

Lee EJ,
Lee HJ,
Hyun MK, et al
. Rupture rate for patients with untreated unruptured intracranial aneurysms in South Korea during 2006–2009. J Neurosurg 2012;117:53–59 doi:10.3171/2012.3.JNS111221 pmid:22519434
CrossRef PubMed

[13] Lee EJ,

[14] Lee HJ,

[15] Hyun MK, et al

[16] 4.↵

Juvela S,
Porras M,
Poussa K
. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. J Neurosurg 2000;93:379–87 pmid:10969934
CrossRef PubMed

[18] Juvela S,

[19] Porras M,

[20] Poussa K

[21] 5.↵
Unruptured intracranial aneurysms–risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Engl J Med 1998:339:1725–33 doi:10.1056/NEJM199812103392401 pmid:9867550
CrossRef PubMed

[22] 6.↵

Juvela S,
Poussa K,
Lehto H, et al
. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. Stroke 2013;44:2414–21 doi:10.1161/STROKEAHA.113.001838 pmid:23868274
Abstract/FREE Full Text

[24] Juvela S,

[25] Poussa K,

[26] Lehto H, et al

[27] 7.↵

Morita A,
Kirino T, et al
UCAS Japan Investigators, Morita A, Kirino T, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012;366:2474–82 doi:10.1056/NEJMoa1113260 pmid:22738097
CrossRef PubMed

[29] Morita A,

[30] Kirino T, et al

[31] 8.↵

Wiebers DO,
Whisnant JP,
Huston J, et al
. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003:362:103–10 doi:10.1016/S0140-6736(03)13860-3 pmid:12867109
CrossRef PubMed

[33] Wiebers DO,

[34] Whisnant JP,

[35] Huston J, et al

[36] 9.↵

Thornton J,
Aletich VA,
Debrun GM, et al
. Endovascular treatment of paraclinoid aneurysms. Surg Neurol 2000;54:288–99 doi:10.1016/S0090-3019(00)00313-X pmid:11136984
CrossRef PubMed

[38] Thornton J,

[39] Aletich VA,

[40] Debrun GM, et al

[41] 10.↵

Wang Y,
Li Y,
Jiang C, et al
. Endovascular treatment of paraclinoid aneurysms: 142 aneurysms in one centre. J Neurointerv Surg 2013;5:552–56 doi:10.1136/neurintsurg-2012-010494 pmid:23087381
Abstract/FREE Full Text

[43] Wang Y,

[44] Li Y,

[45] Jiang C, et al

[46] 11.↵

Sun Y,
Li Y,
Li A
. Endovascular treatment of paraclinoid aneurysms. Interv Neuroradiol 2011;17:425–30 pmid:22192545
Abstract/FREE Full Text

[48] Sun Y,

[49] Li Y,

[50] Li A

[51] 12.↵

Sorimachi T,
Ito Y,
Morita K, et al
. Long-term follow-up of intra-aneurysmal coil embolization for unruptured paraclinoid aneurysms. Neurol Res 2012;34:864–70 doi:10.1179/1743132812Y.0000000084 pmid:22889587
CrossRef PubMed

[53] Sorimachi T,

[54] Ito Y,

[55] Morita K, et al

[56] 13.↵

Park HK,
Horowitz M,
Jungreis C, et al
. Endovascular treatment of paraclinoid aneurysms: experience with 73 patients. Neurosurgery 2003;53:14–23; discussion 24 doi:10.1227/01.NEU.0000068789.08955.1C pmid:12823869
CrossRef PubMed

[58] Park HK,

[59] Horowitz M,

[60] Jungreis C, et al

[61] 14.↵

Kwon BJ,
Im S-H,
Park JC, et al
. Shaping and navigating methods of microcatheters for endovascular treatment of paraclinoid aneurysms. Neurosurgery 2010;67:34–40 doi:10.1227/01.NEU.0000370891.67129.2F pmid:20559090
CrossRef PubMed

[63] Kwon BJ,

[64] Im S-H,

[65] Park JC, et al

[66] 15.↵

D'Urso PI,
Karadeli HH,
Kallmes DF, et al
. Coiling for paraclinoid aneurysms: time to make way for flow diverters? AJNR Am J Neuroradiol 2012;33:1470–74 doi:10.3174/ajnr.A3009 pmid:22403773
Abstract/FREE Full Text

[68] D'Urso PI,

[69] Karadeli HH,

[70] Kallmes DF, et al

[71] 16.↵

al-Rodhan NR,
Piepgras DG,
Sundt TM
. Transitional cavernous aneurysms of the internal carotid artery. Neurosurgery 1993;33:993–96; discussion 997–98 doi:10.1227/00006123-199312000-00006 pmid:8134013
CrossRef PubMed

[73] al-Rodhan NR,

[74] Piepgras DG,

[75] Sundt TM

[76] 17.↵

Iihara K,
Murao K,
Sakai N, et al
. Unruptured paraclinoid aneurysms: a management strategy. J Neurosurg 2003;99:241–47 doi:10.3171/jns.2003.99.2.0241 pmid:12924695
CrossRef PubMed

[78] Iihara K,

[79] Murao K,

[80] Sakai N, et al

[81] 18.↵

Ng P,
Khangure MS,
Phatouros CC, et al
. Endovascular treatment of intracranial aneurysms with Guglielmi detachable coils: analysis of midterm angiographic and clinical outcomes. Stroke 2002;33:210–17 doi:10.1161/hs0102.100486 pmid:11779912
Abstract/FREE Full Text

[83] Ng P,

[84] Khangure MS,

[85] Phatouros CC, et al

[86] 19.↵

Vlak MH,
Algra A,
Brandenburg R, et al
. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 2011;10:626–36 doi:10.1016/S1474-4422(11)70109-0 pmid:21641282
CrossRef PubMed

[88] Vlak MH,

[89] Algra A,

[90] Brandenburg R, et al

[91] 20.↵

Ferrell AS,
Lessne ML,
Alexander MJ, et al
. Visual complications after stent-assisted endovascular embolization of paraophthalmic and suprasellar variant superior hypophyseal aneurysms: the Duke Cerebrovascular Center experience in 57 patients. World Neurosurg 2012:78:289–94 doi:10.1016/j.wneu.2011.12.003 pmid:22381310
CrossRef PubMed

[93] Ferrell AS,

[94] Lessne ML,

[95] Alexander MJ, et al

[96] 21.↵

Yadla S,
Campbell PG,
Grobelny B, et al
. Open and endovascular treatment of unruptured carotid-ophthalmic aneurysms: clinical and radiographic outcomes. Neurosurgery 2011;68:1434–43; discussion 1443 doi:10.1227/NEU.0b013e31820b4f85 pmid:21273934
CrossRef PubMed

[98] Yadla S,

[99] Campbell PG,

[100] Grobelny B, et al

[101] 22.↵

Fang S,
Lanzino G
. Paraclinoid aneurysms: is there a new endovascular standard? Neurol Res 2014;36:314–22 doi:10.1179/1743132814Y.0000000326 pmid:24617932
CrossRef PubMed

[103] Fang S,

[104] Lanzino G

[105] 23.↵

Kim LJ,
Tariq F,
Levitt M, et al
. Multimodality treatment of complex unruptured cavernous and paraclinoid aneurysms. Neurosurgery 2014;74:51–61; discussion 61; quiz 61 doi:10.1227/NEU.0000000000000192 pmid:24089048
CrossRef PubMed

[107] Kim LJ,

[108] Tariq F,

[109] Levitt M, et al

[110] 24.↵

Lanzino G,
Crobeddu E,
Cloft HJ, et al
. Efficacy and safety of flow diversion for paraclinoid aneurysms: a matched-pair analysis compared with standard endovascular approaches. AJNR Am J Neuroradiol 2012;33:2158–61 doi:10.3174/ajnr.A3207 pmid:22790243
Abstract/FREE Full Text

[112] Lanzino G,

[113] Crobeddu E,

[114] Cloft HJ, et al

[115] 25.↵

Loumiotis I,
D'Urso PI,
Tawk R, et al
. Endovascular treatment of ruptured paraclinoid aneurysms: results, complications, and follow-up. AJNR Am J Neuroradiol 2012;33:632–37 doi:10.3174/ajnr.A2825 pmid:22173755
Abstract/FREE Full Text

[117] Loumiotis I,

[118] D'Urso PI,

[119] Tawk R, et al

[120] 26.↵

Shigematsu T,
Fujinaka T,
Yoshimine T, et al
. Endovascular therapy for asymptomatic unruptured intracranial aneurysms: JR-NET and JR-NET2 findings. Stroke 2013;44:2735–42 doi:10.1161/STROKEAHA.111.000609 pmid:23899916
Abstract/FREE Full Text

[122] Shigematsu T,

[123] Fujinaka T,

[124] Yoshimine T, et al

[125] 27.↵

Sonobe M,
Yamazaki T,
Yonekura M, et al
. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke 2010;41:1969–77 doi:10.1161/STROKEAHA.110.585059 pmid:20671254
Abstract/FREE Full Text

[127] Sonobe M,

[128] Yamazaki T,

[129] Yonekura M, et al

[130] 28.↵

Delgado Almandoz JE,
Crandall BM,
Scholz JM, et al
. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline embolization device. J Neurointerv Surg 2013;5(suppl 3):iii3–10 doi:10.1136/neurintsurg-2012-010582 pmid:23314576
Abstract/FREE Full Text

[132] Delgado Almandoz JE,

[133] Crandall BM,

[134] Scholz JM, et al

[135] 29.↵

Delgado Almandoz JE,
Kadkhodayan Y,
Crandall BM, et al
. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. J Neurointerv Surg 2014;6:767–73 doi:10.1136/neurintsurg-2013-010976 pmid:24353331
Abstract/FREE Full Text

[137] Delgado Almandoz JE,

[138] Kadkhodayan Y,

[139] Crandall BM, et al

[140] 30.↵

Lee DH,
Kim HS,
Kim SM, et al
. Change of platelet reactivity to antiplatelet therapy after stenting procedure for cerebral artery stenosis: VerifyNow antiplatelet assay before and after stenting. Neurointervention 2012;7:23–6 doi:10.5469/neuroint.2012.7.1.23 pmid:22454781
CrossRef PubMed

[142] Lee DH,

[143] Kim HS,

[144] Kim SM, et al

[145] 31.↵

Kang H-S,
Kwon BJ,
Kim JE, et al
. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206–10 doi:10.3174/ajnr.A2051 pmid:20223886
Abstract/FREE Full Text

[147] Kang H-S,

[148] Kwon BJ,

[149] Kim JE, et al

Main menu

User menu

Search

American Journal of Neuroradiology

Endovascular Treatment of Unruptured Paraclinoid Aneurysms: Single-Center Experience with 400 Cases and Literature Review

Abstract

ABBREVIATION:

Materials and Methods

Study Population

Endovascular Procedures

Angiographic Outcomes and Follow-Up

Statistical Analysis

Results

Demographics

Treatment Specifics

Angiographic Outcomes

Procedure-Related Complications

Long-Term Clinical Outcome

Discussion

Conclusions

Footnotes

REFERENCES

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

INTERVENTIONAL

ADULT BRAIN

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology

Main menu

User menu

Search

Endovascular Treatment of Unruptured Paraclinoid Aneurysms: Single-Center Experience with 400 Cases and Literature Review

Abstract

ABBREVIATION:

Materials and Methods

Study Population

Endovascular Procedures

Angiographic Outcomes and Follow-Up

Statistical Analysis

Results

Demographics

Treatment Specifics

Angiographic Outcomes

Procedure-Related Complications

Long-Term Clinical Outcome

Discussion

Conclusions

Footnotes

REFERENCES

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

INTERVENTIONAL

ADULT BRAIN

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology